1h Free Analyst Time
The publisher has been monitoring the brain tumor therapeutics market and it is poised to grow by $1.23 billion during 2021-2025, progressing at a CAGR of 9.67% during the forecast period. The report on the brain tumor therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of brain cancer and strategic alliances.
The brain tumor therapeutics market analysis includes the type segment and geographic landscape.
The brain tumor therapeutics market is segmented as below:
By Type
- Small molecules
- Biologics
By Geographic
- North America
- Europe
- Asia
- ROW
This study identifies the high morbidity of brain tumors as one of the prime reasons driving the brain tumor therapeutics market growth during the next few years.
The report on brain tumor therapeutics market covers the following areas:
- Brain tumor therapeutics market sizing
- Brain tumor therapeutics market forecast
- Brain tumor therapeutics market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading brain tumor therapeutics market vendors that include Amgen Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., NextSource Pharmaceuticals LLC, Novartis AG, and Y-mAbs Therapeutics Inc. Also, the brain tumor therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Small molecules - Market size and forecast 2020-2025
- Biologics - Market size and forecast 2020-2025
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Amgen Inc.
- Bristol-Myers Squibb Co.
- Eisai Co. Ltd.
- Emcure Pharmaceuticals Ltd.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- NextSource Pharmaceuticals LLC
- Novartis AG
- Y-mAbs Therapeutics Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Type - Market share 2020-2025 (%)
- Comparison by Type
- Small molecules - Market size and forecast 2020-2025 ($ million)
- Small molecules - Year-over-year growth 2020-2025 (%)
- Biologics - Market size and forecast 2020-2025 ($ million)
- Biologics - Year-over-year growth 2020-2025 (%)
- Market opportunity by Type
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Amgen Inc. - Overview
- Amgen Inc. - Business segments
- Amgen Inc. - Key offerings
- Amgen Inc. - Key customers
- Amgen Inc. - Segment focus
- Bristol-Myers Squibb Co. - Overview
- Bristol-Myers Squibb Co. - Product and service
- Bristol-Myers Squibb Co. - Key offerings
- Bristol-Myers Squibb Co. - Key customers
- Bristol-Myers Squibb Co. - Segment focus
- Eisai Co. Ltd. - Overview
- Eisai Co. Ltd. - Business segments
- Eisai Co. Ltd. - Key offerings
- Eisai Co. Ltd. - Key customers
- Eisai Co. Ltd. - Segment focus
- Emcure Pharmaceuticals Ltd. - Overview
- Emcure Pharmaceuticals Ltd. - Product and service
- Emcure Pharmaceuticals Ltd. - Key offerings
- Emcure Pharmaceuticals Ltd. - Key customers
- Emcure Pharmaceuticals Ltd. - Segment focus
- F. Hoffmann-La Roche Ltd. - Overview
- F. Hoffmann-La Roche Ltd. - Business segments
- F. Hoffmann-La Roche Ltd. - Key offerings
- F. Hoffmann-La Roche Ltd. - Key customers
- F. Hoffmann-La Roche Ltd. - Segment focus
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Key customers
- GlaxoSmithKline Plc - Segment focus
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Key customers
- Merck and Co. Inc. - Segment focus
- NextSource Pharmaceuticals LLC - Overview
- NextSource Pharmaceuticals LLC - Product and service
- NextSource Pharmaceuticals LLC - Key offerings
- NextSource Pharmaceuticals LLC - Key customers
- NextSource Pharmaceuticals LLC - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Y-mAbs Therapeutics Inc. - Overview
- Y-mAbs Therapeutics Inc. - Business segments
- Y-mAbs Therapeutics Inc. - Key offerings
- Y-mAbs Therapeutics Inc. - Key customers
- Y-mAbs Therapeutics Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global brain tumor therapeutics market: Amgen Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., NextSource Pharmaceuticals LLC, Novartis AG, and Y-mAbs Therapeutics Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is high morbidity of brain tumors.'
According to the report, one of the major drivers for this market is the increasing prevalence of brain cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Bristol-Myers Squibb Co.
- Eisai Co. Ltd.
- Emcure Pharmaceuticals Ltd.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- NextSource Pharmaceuticals LLC
- Novartis AG
- Y-mAbs Therapeutics Inc.
